Sign In
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
Kolkata: The flow of applications for public issues to capital markets regulator Sebi is continuing. On Dec 19 Madhya Pradesh-based drug maker Symbiotec Pharmalab submitted preliminary papers with capital markets regulator Sebi to raise Rs 2,180 crore through an IPO. According to early blueprint, it will be raised via a combination of a fresh issue of shares worth Rs 150 crore and a much-larger OFS (offer for sale) part worth) Rs 2,030 crore.
The OFS segment will witness promoter Satwani Holdings LLP and investors, Rosewood Investments, and India Business Excellence Fund-III diluting tehri stake. Rosewood Investments and India Business Excellence Fund cumulatively more than 66% stake in the company. According to the DHRP, the fresh issue proceeds will be deployed to retire debt payment and for general corporate purposes. JM Financial, Motilal Oswal Investment Advisors, Nomura Financial Advisory and Securities (India) have been appointed as merchant bankers. According to reports, the firm can also raise about Rs 30 crore in a pre-IPO round before floating the public issue.
The company is headquartered in Indore. The firm is focused on research and development ad its core competence lies in three domains -- organic chemistry, biotechnology and complex injectables. What is worthy to note is that it is a leader in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). The company has a couple of API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres. It also claims a global leadership position in corticosteroid and steroidal-hormone active APIs with a global market share (by volume) of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs.
The listed peers of the company includes Concord Biotech, Divi's Laboratories, Cohance Lifesciences and Laurus Labs.
Symbiotec posted a profit of Rs 29.9 crore in Q1FY26. IN this period, its revenue was Rs 203.1 crore. The FY25 profit figures was Rs 96.8 crore, which marked a decline of 3.3% against Rs 100 crore in FY24. But between FY24 and FY25 there was a rise of 5% in revenue which stood at Rs 751.6 crore in FY25.
(Disclaimer: This article is only meant to provide information. TV9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, precious metals, commodity, any form of alternative investment instruments and crypto assets.)
